Unilife
Unilife launched its Autoinfusor continuous delivery tech on a commercial scale for the first time.
The platform – a range of devices which can inject or infuse doses from 2ml to 15ml – works by delivering medication over a set period of time.
Stephen Allan, VP of marketing and communications, told in-PharmaTechnologist the firm decided to roll-out the collection after receiving a number of demands from pharma companies in need of larger dose continuous delivery.
“The need is for larger dose and more viscous therapies that can be administered in the comfort of the patient’s own home.”
The firm is now developing its tech to suit the needs of those companies, and is on the lookout for more commercial opportunities.